• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Excelimmune

edit

Excelimmune, Inc. is a biopharmaceutical company specializing in the development of fully human recombinant polyclonal antibodies for therapeutic use. This technology is applicable in the treatment of infectious diseases, as well as protein diseases and cancer.

Milestones

edit

• 
  Excelimmune received $12M in Series C funding. (12/20/11)
  Posted 12/20/11 at 6:51pm via finsmes.com
• 
  Excelimmune received $10.5M in Series B funding. (5/31/11)
  Posted 5/31/11 at 6:30pm via masshightech.com
• 
  Excelimmune received $4.5M in Venture Round funding. (7/7/10)
  Posted 7/7/10 at 8:24pm via fiercebiotech.com
• 
  Excelimmune received $1M in Series B funding. (4/14/10)
  Posted 4/27/10 at 12:19am via onbiovc.com

Videos

Screenshots

edit

Sources

1. Excelimmune, Inc.: Series B $1M (onbiovc.com) [edit]
2. Excelimmune garners $4.5M in new financing (fiercebiotech.com) [edit]
3. MRSA-focused biotech Excelimmune raises $10.5M (masshightech.com) [edit]
4. Excelimmune Raises $12M (finsmes.com) [edit]